Cytek Biosciences, Inc.
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
CTKB$5.79-1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| (In thousands, except share and per share data) | 2026 | 2025 | 2026 | 2025 |
| Revenue, net: | ||||
| Product | $32,556 | $31,415 | $61,335 | $59,525 |
| Service | 15,584 | 14,187 | 30,940 | 27,534 |
| Total revenue, net | 48,140 | 45,602 | 92,275 | 87,059 |
| Cost of sales: | ||||
| Product | 12,884 | 14,921 | 28,805 | 30,450 |
| Service | 6,916 | 6,814 | 13,876 | 12,585 |
| Total cost of sales | 19,800 | 21,735 | 42,681 | 43,035 |
| Gross profit | 28,340 | 23,867 | 49,594 | 44,024 |
| Operating expenses: | ||||
| Research and development | 9,741 | 8,826 | 19,345 | 18,550 |
| Sales and marketing | 13,174 | 12,134 | 24,820 | 24,643 |
| General and administrative | 16,825 | 13,531 | 35,292 | 26,429 |
| Total operating expenses | 39,740 | 34,491 | 79,457 | 69,622 |
| Loss from operations | (11,400) | (10,624) | (29,863) | (25,598) |
| Other income (expense): | ||||
| Interest expense | (281) | (414) | (543) | (705) |
| Interest income | 819 | 555 | 1,606 | 1,063 |
| Other income (expense), net | (781) | 3,708 | (216) | 7,199 |
| Total other income (expense), net | (243) | 3,849 | 847 | 7,557 |
| Loss before income taxes | (11,643) | (6,775) | (29,016) | (18,041) |
| Provision for (benefit from) income taxes | 515 | (1,192) | 2,008 | (1,056) |
| Net loss | $(12,158) | $(5,583) | $(31,024) | $(16,985) |
| Net loss, basic and diluted | $(12,158) | $(5,583) | $(31,024) | $(16,985) |
| Net loss per share, basic and diluted | $(0.09) | $(0.04) | $(0.24) | $(0.13) |
| Weighted-average shares used in calculating net loss per share, basic and diluted | 129,460,518 | 126,934,294 | 129,084,814 | 127,632,999 |
| Comprehensive loss: | ||||
| Net loss | $(12,158) | $(5,583) | $(31,024) | $(16,985) |
| Foreign currency translation adjustment, net of tax | 517 | 603 | 845 | 43 |
| Unrealized loss on marketable securities | (147) | (33) | (348) | (98) |
| Net comprehensive loss | $(11,788) | $(5,013) | $(30,527) | $(17,040) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.